How To Get Ahead In Canada's Private Market: Product Listing Agreements
This article was originally published in Scrip
Canada's private pharmaceutical market is a big and growing opportunity for companies, but taking a piece of the pie is not as easy as it used to be, says Arvind Mani, director of market access and policy research at PDCI Market Access (PDCI), a Canadian pricing and reimbursement consultancy. Private insurers are starting to worry about cost containment and according to PDCI, product listing agreements could become a prerequisite for companies selling expensive specialty drugs. In an interview with Scrip, Mani explained what companies need to know about these agreements to get ahead.
You may also be interested in...
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.